Peptides for Women: What Changes, What Is Off Limits, and What to Ask

The perimenopausal transition typically begins in the forties and runs for several years before periods stop. Ovarian hormone output fluctuates rather than declining smoothly, and progesterone tends to fall earlier and more erratically than estrogen. The downstream effects are exactly the symptoms presented as sleep, weight, skin, hair, mood or desire problems. A peptide can be a reasonable tool for one of those symptoms. It is not a treatment for the transition.

Peptides do not replace menopausal hormone therapy. If the transition is the driver, it belongs in the conversation with your physician rather than being treated around.

Fatigue, hair shedding, cold intolerance, brain fog and low mood are the classic presentation of iron deficiency and of an underactive thyroid, both far more common in women than in men: iron deficiency because of menstrual blood loss, thyroid disease because autoimmune thyroiditis is heavily skewed toward women. Ferritin can be low while a full blood count reads normal, so a normal hemoglobin is not a clearance. Neither responds to a peptide, and both are inexpensive to find.

Slow-wave sleep is when the largest growth hormone pulse of the day occurs; a 2000 paper in JAMA described both declining together across adult life, in healthy men. Night sweats and progesterone loss fragment exactly this stage, which is the mechanistic rationale, not a trial result, for dosing GH-axis peptides at bedtime.

Bone is the other structural point. Weight lost on a GLP-1 is not all fat; a portion is lean tissue, and at this level of appetite suppression most people under-eat protein without noticing. For women, bone loss accelerates around and after menopause regardless. The answer is not to avoid the medication when weight is the problem; it is that resistance training and a protein target belong in the prescription.

In women, low desire is usually multifactorial: sleep, pain with intercourse, relationship context, medications such as SSRIs, and the transition itself. PT-141 acts on melanocortin receptors in the brain rather than on blood flow, which is why the FDA-approved product built on it is indicated only for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and only when the low desire is not explained by a medical or psychiatric condition, a relationship problem, or a medication.

SERENITY combines DSIP, Selank, CJC-1295 and ipamorelin in one vial, directed at bedtime. DSIP, delta sleep-inducing peptide, is described as acting on sleep architecture rather than as a sedative; CJC-1295, a growth-hormone-releasing hormone analogue, and ipamorelin, a ghrelin-receptor agonist, each prompt a pulse of the body's own growth hormone; Selank is included for its described effects on anxiety.

The human data is oldest for DSIP: small double-blind studies from the 1980s and early 1990s, mostly intravenous, in chronic insomnia, with mixed results, summarized in European Neurology in 1986 and revisited in Neuropsychobiology in 1992; a 2006 review in the Journal of Neurochemistry still called it "an unresolved riddle." A 2006 study in the Journal of Clinical Endocrinology and Metabolism reported sustained growth hormone and IGF-1 increases in healthy adults after CJC-1295. The 1998 European Journal of Endocrinology paper that characterized ipamorelin as selective is animal and cell work; its one randomized human trial, in the International Journal of Colorectal Disease in 2014, was for post-operative bowel recovery by a different route. There are no randomized human trials of SERENITY, of subcutaneous DSIP, or of this combination for sleep in women. It suits a woman with fragmented, non-restorative sleep, once the transition, thyroid, alcohol, caffeine, sleep apnea and existing mental-health care have been discussed. Bloodwork is commonly required first.

Semaglutide is an analogue of GLP-1, the gut hormone that prompts insulin, suppresses glucagon, slows stomach emptying and acts on appetite centers in the brain. The compounded preparation shares its active ingredient with the branded products, not their approval.

It is the best-evidenced product on the page. STEP 1, in the New England Journal of Medicine in 2021, randomized 1,961 adults without diabetes to weekly semaglutide 2.4 mg or placebo with lifestyle intervention; mean weight change at 68 weeks was −14.9% against −2.4%. STEP 5 in Nature Medicine in 2022 extended that to two years, and SELECT in the New England Journal in 2023 reported cardiovascular outcomes. Women made up the majority of participants in the STEP obesity trials. Semaglutide suits a woman for whom weight is the actual problem, who has a contraception plan, and who is not pregnant, breastfeeding or trying to conceive. Best peptides for weight loss compares it with tirzepatide.

Tirzepatide acts at both the GLP-1 and the GIP receptor. SURMOUNT-1, in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to weekly tirzepatide 5, 10 or 15 mg or placebo for 72 weeks; mean weight change was −15.0%, −19.5% and −20.9% against −3.1%. SURMOUNT-2 in The Lancet in 2023 repeated the design in type 2 diabetes, and SURMOUNT-5 in the New England Journal in 2025 compared tirzepatide with semaglutide head to head.

For women, tirzepatide carries one instruction semaglutide's label does not. The Zepbound and Mounjaro labels direct patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase; contraceptives not taken by mouth are unaffected. A physician prescribing compounded tirzepatide should apply it. The choice between the two GLP-1s is the physician's, informed by the head-to-head data, tolerability and the cost on each product's page.

GHK-Cu is glycine-histidine-lysine bound to a copper ion. It occurs naturally in human plasma, declines with age, and acts as a copper carrier for copper-dependent enzymes; research describes increased synthesis of collagen, elastin and proteoglycans, from cultured fibroblasts in FEBS Letters in 1988 and rat wounds in the Journal of Clinical Investigation in 1993 to a 2015 review in BioMed Research International and in-vitro work on human hair follicles in Archives of Pharmacal Research in 2007.

The human evidence is topical. A 1994 study in Wound Repair and Regeneration reported improved healing of diabetic ulcers, and a 2006 randomized study in Archives of Facial Plastic Surgery applied GHK-Cu skin care after CO2 laser resurfacing in 13 patients: blinded evaluators found no objective difference in redness or wrinkles, while patient-reported satisfaction was higher. There are no randomized human trials of injectable GHK-Cu for skin, hair or anything else, in either sex. It suits a woman whose priority is skin texture and laxity through the transition, or diffuse thinning once ferritin and thyroid are checked, alongside retinoids and sun protection. Peptides for skin and peptides for hair growth go deeper.

RADIANCE pairs GHK-Cu with tesamorelin, a growth-hormone-releasing hormone analogue that is an FDA-approved active ingredient: Egrifta SV is approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, on trials including the 2007 New England Journal of Medicine study and a 2010 pooled phase 3 analysis in the Journal of Clinical Endocrinology and Metabolism. Two facts from that label matter for women: Egrifta SV is contraindicated in pregnancy, and its limitations of use state it is not indicated for weight loss because its effect is weight-neutral. RADIANCE suits a woman who wants the skin case for GHK-Cu and whose physician also thinks a GHRH analogue is appropriate. Bloodwork is commonly required first.

PT-141 + Oxytocin combines bremelanotide with oxytocin, the nine-amino-acid hormone with established roles in labor, lactation and bonding. PT-141 has the most relevant women's data of any peptide Pepti prescribes. RECONNECT, two identical 24-week phase 3 trials in Obstetrics and Gynecology in 2019, randomized 1,267 premenopausal women with hypoactive sexual desire disorder to bremelanotide 1.75 mg as needed or placebo and reported statistically significant increases in desire and reductions in desire-related distress, with nausea, flushing and headache each in 10% or more of treated women. A 2022 paper in the Journal of Women's Health summarized safety across the program. The FDA approved that product, Vyleesi, on 21 June 2019.

The compounded PT-141 here is not Vyleesi and does not carry its approval, and the blend adds oxytocin, for which the women's evidence is thin: a 2015 randomized crossover trial in Fertility and Sterility gave intranasal oxytocin or placebo to 30 pre- and postmenopausal women with sexual dysfunction and found both groups improved with no significant difference. There are no randomized trials of subcutaneous oxytocin, or of this combination. The blend suits a woman whose low desire persists after sleep, pain, medications and relationship context have been addressed, whose blood pressure is controlled, and who understands nausea is the common side effect: the Vyleesi label reports it in 40% of women, needing an anti-nausea medication in 13% and leading to discontinuation in 8%.

NAD+ is the coenzyme every cell uses to move electrons in energy metabolism and to fuel the sirtuin and PARP enzymes of DNA repair; a 2012 paper in PLOS ONE described NAD+ in human tissue falling with age. The women's data is real but is not about the injection. A 2021 randomized trial in Science gave oral nicotinamide mononucleotide, an NAD+ precursor, or placebo for ten weeks to postmenopausal women with prediabetes who were overweight or obese, and reported increased muscle insulin sensitivity with NMN and no change with placebo. There are no randomized trials of subcutaneous NAD+ injection for fatigue in either sex. NAD+ suits a woman whose energy complaint survives a normal ferritin, thyroid and metabolic panel and a candid conversation about sleep, and whose physician thinks the mechanistic case is worth a trial of treatment.

Semaglutide and tirzepatide are FDA-approved active ingredients; the compounded versions are not approved products. The FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025, and shortage-based compounding has ended. What remains is the patient-specific 503A pathway, under which a state-licensed pharmacy may compound for a named patient where the prescriber determines and documents a change that produces a significant difference for that patient. On 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which concerns outsourcing facilities making batches; it is a proposal, not a final rule.

None of the four is in Category 2 of the FDA's 503A interim list today. The FDA's safety-risks page, current as of 22 April 2026, lists CJC-1295, emideltide (DSIP), ipamorelin acetate and Selank among substances "nominated but withdrawn" from Category 2; ipamorelin acetate still carries a separate 503B Category 2 entry, which applies to outsourcing facilities, not to a 503A pharmacy compounding to a prescription. The interim list updated 14 May 2026 shows 503A Category 2 down to six substances, none of them a SERENITY component.

The advisory votes are separate. On 29 October 2024 the Pharmacy Compounding Advisory Committee voted 0–12 with one abstention against adding ipamorelin to the 503A Bulks List for growth hormone deficiency and post-operative ileus. On 4 December 2024 it voted 0–13 against CJC-1295 free base and 1–12 against CJC-1295 acetate. On 24 July 2026 it voted 6–7 with one abstention on emideltide, the only one of seven peptides reviewed that week not to receive a favorable vote. Those votes are advisory; the FDA has issued no final determination on any of the four, a "no" vote is not a ban, and all four remain legal for a physician to prescribe and a state-licensed pharmacy to dispense.

Injectable GHK-Cu was placed in Category 2 in September 2023 and was among the peptides the FDA removed on 15 April 2026; the safety-risks page now lists it as withdrawn. The 14 May 2026 update records non-injectable GHK-Cu restored to Category 1 after a nominator clarified on 5 May 2026 that it had withdrawn only the injectable route, and says the FDA intends to consult the advisory committee on GHK-Cu before the end of February 2027. Tesamorelin is a component of an FDA-approved drug and does not depend on the bulks list.

Bremelanotide and oxytocin are both components of FDA-approved drug products, one of the three routes under which a 503A pharmacy may compound with a bulk substance; neither appears in any category of the 14 May 2026 interim list, and neither was on the July 2026 advisory agenda. The compounded blend is not Vyleesi and not the hospital oxytocin product. Nicotinamide adenine dinucleotide sits in Category 1, "bulk drug substances under evaluation," in the same list; the FDA does not intend to act against a compounder using a Category 1 substance while evaluation is pending, provided the interim-policy conditions are met.

The 2026 WADA Prohibited List names CJC-1295, sermorelin and tesamorelin under growth hormone-releasing hormone analogues and ipamorelin under growth hormone secretagogues, all prohibited at all times; GHK-Cu, bremelanotide, oxytocin, semaglutide and tirzepatide are not named.

Not a caution, not a lower dose. No peptide in this catalog has safety data in pregnancy or lactation, and several act on growth signaling or appetite regulation in ways nobody would knowingly introduce to a pregnancy. The branded labels say it in their own terms. Wegovy directs that the drug be stopped when a pregnancy is recognized and at least two months before a planned pregnancy because of semaglutide's long half-life, and reports no human data on the drug in breast milk. Zepbound directs discontinuation when pregnancy is recognized; its label describes a single-dose lactation study in which tirzepatide in breast milk was undetectable or low, with no data on effects on the infant, which is not a clearance. Egrifta SV is contraindicated in pregnancy outright, and the Vyleesi label tells women to use effective contraception during treatment and stop if pregnancy is suspected. If you are pregnant, trying to conceive, or breastfeeding, the answer is no. Can you take peptides while pregnant covers why.

Two issues sit inside this. Semaglutide and tirzepatide slow gastric emptying, part of how they work, and that can affect how an oral medication is absorbed. The labels diverge: Zepbound and Mounjaro carry the explicit four-week switch-or-barrier instruction above, while the Wegovy label reports that semaglutide 1 mg did not affect absorption of oral medications in clinical pharmacology trials, and still advises monitoring. The underlying study, in the Journal of Clinical Pharmacology in 2015, gave a combined ethinylestradiol/levonorgestrel pill to 43 postmenopausal women with type 2 diabetes before and during semaglutide and found no reduction in either hormone's bioavailability. Separately, weight loss can restore ovulation in a woman who was not ovulating reliably, so fertility may change first. A prescriber should ask what contraception you use, discuss a backup or non-oral method around titration, and agree how far ahead of a planned pregnancy the medication stops. If none of that comes up, raise it. Do peptides affect fertility goes further.

CJC-1295, ipamorelin, sermorelin and tesamorelin raise growth hormone and IGF-1, and GHK-Cu is described as pro-angiogenic. None of that is a proven cancer risk in women, and none of it is nothing: the Egrifta SV label contraindicates tesamorelin in active malignancy and requires any prior malignancy to be inactive with treatment complete. A personal or strong family history of breast, ovarian or endometrial cancer goes on the intake and is the physician's call. The GLP-1 labels carry a boxed warning on thyroid C-cell tumors seen in rodents and contraindicate the drugs in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease: each dose transiently raises systolic pressure by about 6 mmHg and lowers heart rate, peaking two to four hours after injection and resolving within about twelve, and the label reports focal hyperpigmentation in 1% of women, more likely with darker skin and daily dosing. A physician prescribing compounded PT-141 should check blood pressure and ask about skin; the directions are as needed with a monthly cap, never daily. And if you are in perimenopause, the physician should be asking whether the transition itself, including hormone therapy, is on the table before any peptide is prescribed for a symptom it is producing.

Dose increases run on a schedule the physician sets, and the trials behind the numbers above ran 68 to 72 weeks. Gastrointestinal effects cluster around each increase, which is also the window in which the tirzepatide contraception instruction applies.

Prescribers describe the sleep effect as noticed within the first nights to weeks rather than months. Whether it persists should be reviewed against the transition, not in isolation.

Dermal collagen turns over slowly. Prescribers describe skin texture changes over eight to twelve weeks and hair changes, where they occur, over a similar or longer window; a follicle in its resting phase will not show anything for months regardless. None of that is trial-established for the injection.

PT-141 is not a daily medication; it is taken as directed before intimacy, and each dose either helps or does not. Nausea is most common with the first doses. For NAD+, prescribers describe energy changes within the first weeks; there is no trial evidence for the injection, so a physician who suggests a defined trial of treatment and an honest review is behaving well, not hedging.